High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
source
Sponsor:News technical sponsor
Sponsor:News AI sponsor
Sponsor: AI sponsor
Sponsor: AI sponsor